Get started
KUROS BIOSCIENCES AG CHF0.10(POST SPLIT)KUROS BIOSCIENCES AG CHF0.10(POST SPLIT)KUROS BIOSCIENCES AG CHF0.10(POST SPLIT)

KUROS BIOSCIENCES AG CHF0.10(POST SPLIT)

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

0RHR chart


Full chart

0RHR upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪794.02 M‬ CHF
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−0.25 CHF
Net income (FY)
‪−13.73 M‬ CHF
Revenue (FY)
‪33.56 M‬ CHF
Shares float
‪26.06 M‬
Beta (1Y)
1.07

Employees


Employees (FY)
5
Change (1Y)
−1 −16.67%
Revenue / Employee (1Y)
‪6.71 M‬ CHF
Net income / Employee (1Y)
‪−2.75 M‬ CHF

About KUROS N


Sector
Health Technology
Industry
Biotechnology
CEO
Christopher T. Fair
Website
kurosbio.com
Headquarters
Schlieren
Founded
2000
ISIN
CH0325814116
FIGI
BBG00JYV5X59
Kuros Biosciences Ltd. operates as biopharmaceutical company, which engages in developing products for tissue repair and bone regeneration. It operates through the following segments: Medical devices, Pharmaceuticals, and Legacy portfolio. The Medical devices segment includes products such as MagnetOs and Attrax. The Pharmaceuticals segment offers Fibrin-PTH, a drug-biologic combination which promotes targeted and controlled bone formation through the induction of osteoprogenitor cell differentiation, enhancement, of osteoblast proliferation and by increasing the lifespan of bone-forming cells. The Legacy portfolio segment is involved in all other products that do not belong to the group's core business strategy. The company was founded by Didier Cowling in 2000 and is headquartered in Schlieren, Switzerland.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

0RHR news



Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of 0RHR is 21.45 CHF — it has increased by 8.87% in the past 24 hours. Watch KUROS BIOSCIENCES AG CHF0.10(POST SPLIT) stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on LSE exchange KUROS BIOSCIENCES AG CHF0.10(POST SPLIT) stocks are traded under the ticker 0RHR.
0RHR stock has risen by 10.83% compared to the previous week, the month change is a −4.74% fall, over the last year KUROS BIOSCIENCES AG CHF0.10(POST SPLIT) has showed a 516.23% increase.
We've gathered analysts' opinions on KUROS BIOSCIENCES AG CHF0.10(POST SPLIT) future price: according to them, 0RHR price has a max estimate of 19.00 CHF and a min estimate of 19.00 CHF. Watch 0RHR chart and read a more detailed KUROS BIOSCIENCES AG CHF0.10(POST SPLIT) stock forecast: see what analysts think of KUROS BIOSCIENCES AG CHF0.10(POST SPLIT) and suggest that you do with its stocks.
0RHR reached its all-time high on Nov 14, 2024 with the price of 31.85 CHF, and its all-time low was 1.30 CHF and was reached on Mar 16, 2023. View more price dynamics on 0RHR chart.
See other stocks reaching their highest and lowest prices.
0RHR stock is 4.25% volatile and has beta coefficient of 1.07. Track KUROS BIOSCIENCES AG CHF0.10(POST SPLIT) stock price on the chart and check out the list of the most volatile stocks — is KUROS BIOSCIENCES AG CHF0.10(POST SPLIT) there?
Today KUROS BIOSCIENCES AG CHF0.10(POST SPLIT) has the market capitalization of ‪835.83 M‬, it has decreased by −1.46% over the last week.
Yes, you can track KUROS BIOSCIENCES AG CHF0.10(POST SPLIT) financials in yearly and quarterly reports right on TradingView.
KUROS BIOSCIENCES AG CHF0.10(POST SPLIT) is going to release the next earnings report on Mar 12, 2025. Keep track of upcoming events with our Earnings Calendar.
KUROS BIOSCIENCES AG CHF0.10(POST SPLIT) revenue for the last half-year amounts to ‪31.80 M‬ CHF, despite the estimated figure of ‪30.00 M‬ CHF. In the next half-year revenue is expected to reach ‪45.30 M‬ CHF.
0RHR net income for the last half-year is ‪−211.00 K‬ CHF, while the previous report showed ‪−8.68 M‬ CHF of net income which accounts for 97.57% change. Track more KUROS BIOSCIENCES AG CHF0.10(POST SPLIT) financial stats to get the full picture.
No, 0RHR doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 30, 2024, the company has 5.00 employees. See our rating of the largest employees — is KUROS BIOSCIENCES AG CHF0.10(POST SPLIT) on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. KUROS BIOSCIENCES AG CHF0.10(POST SPLIT) EBITDA is ‪−2.30 M‬ CHF, and current EBITDA margin is −18.33%. See more stats in KUROS BIOSCIENCES AG CHF0.10(POST SPLIT) financial statements.
Like other stocks, 0RHR shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade KUROS BIOSCIENCES AG CHF0.10(POST SPLIT) stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So KUROS BIOSCIENCES AG CHF0.10(POST SPLIT) technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating KUROS BIOSCIENCES AG CHF0.10(POST SPLIT) stock shows the buy signal. See more of KUROS BIOSCIENCES AG CHF0.10(POST SPLIT) technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.